Theravance Biopharma, Inc. Defined Contribution Plan, Cost
Theravance Biopharma, Inc. (TBPH) reported Defined Contribution Plan, Cost of $400.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2026-03-23
- Theravance Biopharma, Inc. defined contribution plan, cost for fiscal 2025 was $400.00K, a 0.00% change from fiscal 2024.
- Theravance Biopharma, Inc. defined contribution plan, cost for fiscal 2024 was $400.00K, a 20.00% decline from fiscal 2023.
- Theravance Biopharma, Inc. defined contribution plan, cost for fiscal 2023 was $500.00K, a 16.67% decline from fiscal 2022.
- Theravance Biopharma, Inc. defined contribution plan, cost for fiscal 2022 was $600.00K.
| Period end | Defined Contribution Plan, Cost 12 month |
|---|---|
| 2025-12-31 | $400.00K 10-K · filed 2026-03-23 |
| 2024-12-31 | $400.00K 10-K · filed 2026-03-23 |
| 2023-12-31 | $500.00K 10-K · filed 2025-03-07 |
| 2022-12-31 | $600.00K 10-K · filed 2024-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |